Viking Therapeutics, Inc. Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q4 2014 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Viking Therapeutics, Inc. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q4 2014 to Q4 2023.
  • Viking Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2023 was $119M, a 32.4% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $119M +$29.1M +32.4% Dec 31, 2023 10-K 2024-02-07
Q4 2022 $89.9M +$22.1M +32.6% Dec 31, 2022 10-K 2024-02-07
Q4 2021 $67.8M +$17.5M +34.7% Dec 31, 2021 10-K 2024-02-07
Q4 2020 $50.3M +$12.7M +33.8% Dec 31, 2020 10-K 2022-02-09
Q4 2019 $37.6M +$7.83M +26.3% Dec 31, 2019 10-K 2021-02-17
Q4 2018 $29.8M +$8.98M +43.2% Dec 31, 2018 10-K 2020-02-26
Q4 2017 $20.8M -$1.34M -6.06% Dec 31, 2017 10-K 2019-03-13
Q4 2016 $22.1M +$4.39M +24.8% Dec 31, 2016 10-K 2018-03-07
Q4 2015 $17.7M +$9.32M +111% Dec 31, 2015 10-K 2017-03-21
Q4 2014 $8.4M Dec 31, 2014 10-K 2016-03-08
* An asterisk sign (*) next to the value indicates that the value is likely invalid.